Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib + binimetinib standard-dose versus high-dose in BRAF V600-mutant melanoma brain metastases
NL-OMON49456Phase 2Withdrawn
- Sponsor
- Array BioPharma
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of encorafenib and binimetinib in melanoma and brain metastases (3 arms), sponsored by Array BioPharma. Primary endpoints: Incidence of dose-limiting toxicities, Incidence and severity of adverse events and 2 more. Planned start May 2019; status: withdrawn.
02
Drugs
encorafenibbinimetinib
03
Conditions
melanomabrain metastases
Beyond the preview
Go deeper on NL-OMON49456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49456.